Clinical Trial

FOLFOXIRI Plus Bevacizumab With or Without Atezolizumab as 1st Line Treatment of pMMR and IS IC-High Metastatic Colorectal Cancer Patients.

Study acronym: AtezoTRIBE2
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The aim of this study is to evaluate the efficacy of the addition of Atezolizumab to FOLFOXIRI plus bevacizumab as first line treatment of patients with pMMR and Immunoscore IC-high metastatic colorectal cancer in terms of Progression Free Survival (PFS).
Protocol Amendment History 12 amendments
This ClinicalTrials.gov record has been amended 12 times since 2024-12-12; most recent amendment 2025-12-05.
Trial Details
NCT Number NCT06733038
Lead Sponsor Gruppo Oncologico del Nord-Ovest
Collaborators: Hoffmann-La Roche
Conditions Colorectal Cancer
Enrollment 238 participants
Start Date 2024-11-15
Primary Completion 2028-04-01 (estimated)
Study Completion 2029-04-01 (estimated)
Updated on ClinicalTrials.gov 2025-12-08